The Evolving Landscape of Cancer Stem Cells and Ways to Overcome Cancer Heterogeneity

被引:14
|
作者
Taniguchi, Hiroaki [1 ,2 ]
Suzuki, Yasunori [2 ]
Natori, Yukikazu [3 ]
机构
[1] Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1080071, Japan
[2] Keio Univ Hosp, Clin & Translat Res Ctr, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[3] BioThinkTank Co Ltd, Nishi Ku, 4-10-1-E1706 Minatomirai, Yokohama, Kanagawa 2200012, Japan
关键词
cancer stemness; signaling cascades; in silico approach; cancer heterogeneity; oligonucleotide therapeutics; ACUTE MYELOID-LEUKEMIA; PANCREATIC-CANCER; METASTATIC CAPACITY; THERAPEUTIC TARGET; INITIATING CELLS; OVARIAN-CANCER; IDENTIFICATION; NANOPARTICLES; MARKER; CD44;
D O I
10.3390/cancers11040532
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer stem cells (CSCs) with therapeutic resistance and plasticity can be found in various types of tumors and are recognized as attractive targets for treatments. As CSCs are derived from tissue stem or progenitor cells, and/or dedifferentiated mature cells, their signal transduction pathways are critical in the regulation of CSCs; chronic inflammation causes the accumulation of genetic mutations and aberrant epigenetic changes in these cells, potentially leading to the production of CSCs. However, the nature of CSCs appears to be stronger than the treatments of the past. To improve the treatments targeting CSCs, it is important to inhibit several molecules on the signaling cascades in CSCs simultaneously, and to overcome cancer heterogeneity caused by the plasticity. To select suitable target molecules for CSCs, we have to explore the landscape of CSCs from the perspective of cancer stemness and signaling systems, based on the curated databases of cancer-related genes. We have been studying the integration of a broad range of knowledge and experiences from cancer biology, and also from other interdisciplinary basic sciences. In this review, we have introduced the concept of developing novel strategies targeting CSCs.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
    Magee, Jeffrey A.
    Piskounova, Elena
    Morrison, Sean J.
    [J]. CANCER CELL, 2012, 21 (03) : 283 - 296
  • [32] Resveratrol: Targeting Cancer Stem Cells and ncRNAs to Overcome Cancer Drug Resistance
    Rezakhani, Leila
    Salmani, Sima
    Dashtaki, Masoumeh Eliyasi
    Ghasemi, Sorayya
    [J]. CURRENT MOLECULAR MEDICINE, 2024, 24 (08) : 951 - 961
  • [33] The Evolving Landscape of Pancreatic Cancer
    Krishnan, Mridula
    [J]. JCO ONCOLOGY PRACTICE, 2023, 19 (01) : 35 - +
  • [34] The Epigenetic Landscape of Pancreatic Cancer Stem Cells
    Zagorac, Sladjana
    Garcia-Bermejo, Laura
    Sainz, Bruno, Jr.
    [J]. EPIGENOMES, 2018, 2 (02)
  • [35] Pharmacogenomics and cancer stem cells: a changing landscape?
    Crea, Francesco
    Ana Duhagon, Maria
    Farrar, William L.
    Danesi, Romano
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (08) : 487 - 494
  • [36] Cancer Stem Cells: Current Status and Evolving Complexities
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    [J]. CELL STEM CELL, 2012, 10 (06) : 717 - 728
  • [37] Evolving Strategies for Therapeutically Targeting Cancer Stem Cells
    Talukdar, S.
    Emdad, L.
    Das, S. K.
    Sarkar, D.
    Fisher, P. B.
    [J]. ADVANCES IN CANCER RESEARCH, VOL 131, 2016, 131 : 159 - 191
  • [38] Cancer stem cells: small subpopulation or evolving fraction?
    Enderling, Heiko
    [J]. INTEGRATIVE BIOLOGY, 2015, 7 (01) : 14 - 23
  • [39] Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
    Palomeras, Sonia
    Ruiz-Martinez, Santiago
    Puig, Teresa
    [J]. MOLECULES, 2018, 23 (09):
  • [40] Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance
    Cho, Yena
    Kim, Yong Kee
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10